

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/076,708	02/15/2002	Satish K. Sharma	- 6322.N	1808	
25533 75	590 08/19/2003				
PHARMACIA & UPJOHN			EXAMINER		
301 HENRIET 0228-32-LAW			CHERNYSHEV, OLGA N		
KALAMAZOO, MI 49007			ART UNIT	PAPER NUMBER	
			1646		
	* *		DATE MAILED: 08/19/2003	DATE MAILED: 08/19/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/076,708	SHARMA ET AL.			
Office Action Summary	Examiner	Art Unit			
•	Olga N. Chernyshev	1646			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earmed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply within the statutory minimum of thirty (30 rill apply and will expire SIX (6) MONTHS cause the application to become ABANI	be timely filed i) days will be considered timely. from the mailing date of this communication. DONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
	s action is non-final.	and a second and a second as the second as t			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4) Claim(s) 1-20 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1-20 are subject to restriction and/or e	election requirement.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accep					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No.					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
 a) ☐ The translation of the foreign language prov 15)☐ Acknowledgment is made of a claim for domestic 	visional application has been	received.			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Infor	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)			

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-2 and 5-20, in so far as they are drawn to a method for identifying agents that are inhibitors of tau-beta amyloid complex formation wherein tau polypeptide is identified by SEQ ID NO: 2, classified in class 435, subclass 7.92, for example.
 - II. Claims 1, 3 and 5-20, in so far as they are drawn to a method for identifying agents that are inhibitors of tau-beta amyloid complex formation wherein tau polypeptide is identified by SEQ ID NO: 4, classified in class 435, subclass 7.92, for example.
 - III. Claims 1, 4 and 5-20, in so far as they are drawn to a method for identifying agents that are inhibitors of tau-beta amyloid complex formation wherein tau polypeptide is identified by SEQ ID NO: 6, classified in class 435, subclass 7.92, for example.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I, II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to different methods that recite structurally and functionally distinct

Application/Control Number: 10/076,708

Art Unit: 1646

elements, are not required one for the other, and therefore constitute patentably distinct inventions.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter and non-coextensive literature and sequence searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga N. Chernyshev whose telephone number is (703) 305-1003. The examiner can normally be reached on Monday to Friday 9 AM to 5 PM ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (703) 308-6564. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Art Unit: 1646

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)0. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 872-9306. If this number is out of service, please call the Group receptionist for an alternative number. Faxed draft or informal communications with the examiner should be directed to (703) 308-7939. Official papers should NOT be faxed to (703) 308-7939.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Muy sm

Olga N. Chernyshev, Ph.D.